Glycine antagonists for the treatment of stroke: A literature survey (1997-1999)

IDrugs

Volumn 3, Issue 3, 2000, Pages 318-328

  Micheli, Fabrizio ^a   Pasquarello, Alessandra ^a  

^a GSK   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0000205864     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (92)

1. Watkins JC, Evans RH: Excitatory amino acid transmitters. Annu Rev Pharmacol Toxicol (1981) 21:165-204.
2. Monaghan DT, Bridges RJ, Cotman CW: The excitatory amino acid receptors: their classes, pharmacology, and distinct properties in the function of the central nervous system. Annu Rev Pharmacol Toxicol (1989) 29:365-402.
3. Meldrum B: Protection against ischemic neuronal damage by drugs acting on excitatory neurotransmitters. Cerebrovasc Brain Metab Rev (1990) 2:27-57.
4. McCullogh J: Excitatory amino acid antagonists and their potential for the treatment of ischemic brain damage in man. Br J Clin Pharmacol (1992) 34:106-114.
5. Schehr RS: New treatments for acute stroke. Nature Biotechnol (1996) 14:1549-54.
6. Collingridge GL, Watkins JC: The NMDA receptor. 2nd edition, IRL Press, Oxford, UK (1994).
7. Meldrum B: Excitatory amino acid antagonists. Blackwell, Oxford, UK (1991).
8. Johnson JW, Asher P: Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature (1987) 325:529-531.
9. Kleckner NW, Dingledine R: Requirement for glycine in activation of NMDA-receptors expressed in Xenopus oocytes. Science (1988) 241:835-837.
10. Morris RG, Anderson ME, Lynch GS, Baudry M: Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist, AP5. Nature (1986) 319:774-776.
11. Palefreyman MG, Baron MB: Non-competitive NMDA antagonists, acting on the glycine site. In: Excitatory Amino Acid Antagonists. Meldrum B (Ed), Blackwell, Oxford, UK (1991):101-129.
12. Carter AJ: Regulation of the NMDA receptor channel complex by the strychnine-insensitive glycine site. Drugs Future (1992) 17:595-613.
13. Kemp JA, Leeson PD: The glycine site of the NMDA receptor - five years on. Trends Pharmacol Sci (1993) 14:20-25.
14. Leeson PD, Iversen LL: The glycine site on the NMDA receptor: structure-activity relationships and therapeutic potential. J Med Chem (1994) 37:4053-4067.
15. Iversen LL, Kemp JA: Non-competitive NMDA antagonists as drugs. In: The NMDA receptor. Collingridge GL, Watkins JC (Eds), 2nd edition, IRL Press, Oxford, UK (1994):469-486.
16. Dannhardt G, Kohl BK: The glycine site on the NMDA receptor: stucture-activity relationships and possible therapeutic applications. Curr Med Chem (1998) 5:253-263.
17. Woodward RM, Huettner JE, Tran M, Guastella J, Keana JFW, Weber E: Pharmacology of 5-chloro-7-trifluoromethyl-1,4-dihydro-2,3-quinoxalinedione: a novel systemically active ionotropic glutamate receptor antagonist. J Pharmacol Exp Ther (1995) 275:1209-1218.
18. Cai SX, Kher SM, Zhou ZL, Ilyin V, Espitia SA, Tran M, Hawkinson JE, Woodward RM, Weber E, Keana JFW: Structure-activity relationships of alkyl-and alkoxy-substituted 1,4-dihydroquinoxaline-2,3-diones: potent and systemically active antagonists for the glycine site of the NMDA receptor. J Med Chem (1997) 40:730-738.
19. Acklin P, Allgeier H, Auberson YP, Bischoff S, Ofner S, Sauer D, Schmutz M: 5-Aminomethylquinoxaline-2,3-diones, part III: Arylamide derivatives as highly potent and selective glycine-site NMDA receptor antagonists. Bioorg Med Chem Lett (1998) 8:493-498.
20. Auberson YP, Acklin P, Allgeier H, Biollaz M, Bishoff S, Ofner S, Veenstra SJ: 5-Aminomethylquinoxaline-2,3-diones, part II: N-Arylamide derivatives as novel NMDA/glycine and AMPA antagonists. Bioorg Med Chem Lett (1998) 8:71-74.
21. Auberson YP, Acklin P, Bishoff S, Moretti R, Ofner S, Schmutz M, Veenstra SJ: N-phosphonoalkyl-5-aminomethylquinoxaline-2,3-diones: in vivo active AMPA and NMDA (glycine) antagonists. Bioorg Med Chem Lett (1999) 9:249-254 and references therein.
22. Katayama S, Ae N, Nagata R: Enzymatic resolution of 2-substituted tetrahydroquinolines. Convenient approaches to tricyclic quinoxalinediones as potent NMDA-glycine antagonists. Tetrahedron Asymmetry (1998) 9:4295-4299.
23. Catarzi D, Colotta V, Varano F, Cecchi L, Filacchioni G, Galli A, Costagli C: 4,5- dihydro-1,2,4-triazolo[1,5-a]quinoxalin-4-ones: Excitatory amino acid antagonists with combined glycine/NMDA and AMPA receptor affinity. J Med Chem (1999) 42:2478-2484.
24. Cai SX, Huang JC, Espitia SA, Tran M, Ilyin VI, Hawkinson JE, Woodward RM, Weber E, Keana JFW: 5-(N-Oxyaza)-7-substituted-1,4-dihydroquinoxaline-2,3-diones: novel, systemically active and broad spectrum antagonists for NMDA/glycine, AMPA and kainate receptors. J Med Chem (1997) 40:3679-3686.
25. Cugola A, Donati D, Guameri M, Micheli F, Missio A, Pecunioso A, Reggiani A, Tarzia G, Zanirato V: Synthesis and biological evaluation of pyrido[2,3-b]pyrazine and pyrido[2,3-b]pyrazine-N-oxide as selective glycine antagonists. Bioorg Med Chem Lett (1996) 6:2749-2754.
26. Micheli F, Cugola A, Donati D, Missio A, Pecunioso A, Reggiani A, Tarzia G: 2,3-Dihydro-6,7-dichloro-pyrido[2,3-b]pyrazine-8-oxide as selective glycine antagonist with in vivo activity. Bioorg Med Chem Lett (1997) 5:2129-2132.
27. Varano F, Catarzi D, Colotta V, Cecchi L, Filacchioni G, Galli A, Costagli C: Synthesis, glycine/NMDA and AMPA binding activity of some new 2,5,6-trioxopyrazino[1,2,3-de]quinoxalines and of their restricted analogs 2,5-dioxo-and 4,5-dioxoimidazo[1,5,4-de]quinoxalines. Arch Pharm (1999) 332:201-207.
28. Kim RH, Lee JC, Lee CW, Chung YJ, Jung YS, Seong CM, Park NS: Synthesis and biological evaluation of kynurenic acid-based antagonists of the N-methyl-D-aspartic acid receptor associated glycine binding site. Korean J Med Chem (1997) 7:41-54.
29. Kim RH, Choi JI, Choi SW, Lee KS, Jung YS, Park WK, Seong CM, Park NS: A series of quinoline-2-carboxylic acid derivatives: new potent glycine site NMDA receptor antagonists. Bull Korean Chem Soc (1997) 18:939-945.
30. Lee CW, Lee SH, Jung YS, Park NS, Seong CM: Synthesis and biological activity of 4-(3-aryl-2-oxo- and 2-thioxo-1,3-oxazolidin-5-ylmethoxy)-quinoline-2-carboxylic acids. Korean J Med Chem (1997) 7:90-95.
31. Kim RH, Chung YJ, Lee CW, Kong JY, Jung YS, Seong CM, Park NS: 4-Substituted-kynurenic acid derivatives: a novel class of NMDA receptor glycine site antagonists. Arch Pharm (1997) 20:351-357.
32. Ewan W, Nagata R: Synthesis of tricyclic azakynurenic acids as a new class of NMDA-glycine antagonists using a novel Stille coupling reaction. Synlett (1997) 473-474
33. Baron BM, Harrison BL, Kehne JH, Schmidt CJ, Van Giersbergen PLM, White HS, Siegel BW, Senyah Y, McCloskey TC, Fadayel GM, Taylor VL, Murawsky MK, Nyce P, Salituro FG: Pharmacological characterization of MDL 105,519, an NMDA receptor glycine site antagonist. Eur J Pharmacol (1997) 323:181-192.
34. 3H]MDL 105,519, a radiolabelled antagonist for the N-methyl-D-aspartate-associated glycine site, to pig cortical brain membranes. Neurosci Lett (1997) 226:79-82.
35. Di Fabio R, Capelli AM, Conti N, Cugola A, Donati D, Feriani A, Gastaldi P, Gaviraghi G, Hewkin CT, Micheli F, Missio A, Mugnaini M, Pecunioso A, Quaglia AM, Ratti E, Rossi L, Tedesco G, Trist DG, Reggiani A: Substituted indole-2-carboxylates as in vivo potent antagonists acting at the strychnine-insensitive glycine binding site. J Med Chem (1997) 40:841-850.
36. Di Fabio R, Cugola A, Donati D, Feriani A, Gaviraghi G, Ratti E, Trist DG, Reggiani A: Identification and pharmacological characterzation of GV150526, a novel glycine antagonist as a potent neuroprotective agent Drugs Future (1998) 23:61-69.
37. Di Fabio R, Pentassuglia G: Novel synthesis of ethyl 3-(bromoacetyl)-4,6-dichloro-1H-indole-2-carboxylate as a useful intermediate in the preparation of potential glycine site antagonists. Synth Commun (1998) 28:51-60.
38. Giacobbe S, Baraldi D, Di Fabio R: Unusual synthesis of new glycine antagonists via sequential aldol condensation-lactonization-elimination reaction. Bioorg Med Chem Lett (1998) 8:1689-1692.
39. Di Fabio R, Araldi G, Giacobbe S, Pentassuglia G, Bozzoli A, Cimarosti Z, Maragni P, Rossi T, Reggiani A: Novel class of indole-2-carboxylates as potent glycine site NMDA antagonists. ACS (1997) 213th San Francisco MEDI 178.
40. Micheli F, Di Fabio R, Capelli AM, Cugola A, Cucuruto O, Feriani A, Gastaldi P, Gaviraghi G, Marchioro C, Oriandi A, Pozzan A, Quaglia AM, Reggiani A, van Amsterdam F: Cycloalkyl indol-2-carboxylates as useful tools for mapping the 'north-eastern' region of the glycine binding site associated with the NMDA receptor. Arch Pharm (1999) 332:73-80.
41. Hewkin CT, Di Fabio R, Conti N, Cugola A, Gastaldi P, Micheli F, Quaglia AM: New synthesis of substituted 2-carboxyindole derivatives. Versatile introduction of a carbamoylethynyl moiety at the C(3) position. Arch Pharm (1999) 332:55-58.
42. Micheli F, Di Fabio R, Baraldi D, Conti N, Cugola A, Gastaldi P Giacobbe S, Marchioro C, Mugnaini M, Rossi L, Pecunioso A, Pentassuglia G: Substituted indole-2-carboxylates as potent antagonists of the glycine binding site associated to the NMDA receptor. Arch Pharm (1999) 332:271-278.
43. Kulagowski JJ, Baker R, Curtis NR, Leeson PD, Mawer IM, Moseley AM, Ridgill MP, Rowley M, Stansfield I, Foster AC, Grimwood S, Hill RG, Kemp JA, Marshall GR, Saywell KL, Tricklebank MD: 3′-(Arylmethyl)- and 3′-(aryloxy)-3-phenyl-4-hydroxyquinolin-2(1H)-ones: Orally active antagonists of the glycine site on the NMDA receptor. J Med Chem (1994) 37:1402-1405.
44. Carling RW, Leeson PD, Moore KW, Moyes CR, Duncton M, Hudson ML, Baker R, Foster AC, Grimwood S, Kemp JA, Marshall GR, Tricklebank MD, Saywell KL: 4-Substituted-3-phenylquinolin-2(1H)-ones: acidic and nonacidic glycine site N-methyl-D-aspartate antagonists with in vivo activity. J Med Chem (1997) 40:754-765.
45. Rowley M, Kulagowski JJ, Watt AP, Rathbone D, Stevenson GI, Carling RW, Baker R, Marshall GR, Kemp JA, Foster AC, Grimwood S, Hargreaves R, Hurley C, Saywell KL, Tricklebank MD, Leeson PD: Effect of plasma protein binding on in vivo activity and brain penetration of glycine/NMDA receptor antagonists. J Med Chem (1997) 40:4053-4068.
46. Bare TM: Pyridazino[4,5-b]quinolinediones: novel glycine/ N-methyl-D-aspartate antagonists for the treatment of stroke. J Heterocyclic Chem (1998) 35:1171-1186.
47. Takano K, Tatlisumak T, Formato JE, Carano RAD, Bergmann AG, Pullan LM, Bare TM, Sotak CH, Fisher M: Glycine site antagonist attenuates infarct size in experimental focal ischemia: postmortem and diffusion mapping studies. Stroke (1997) 28:1255-1263.
48. Tatlisumak T, Takano K, Meiler MR, Fisher M: A glycine site antagonist, ZD9379, reduces number of spreading depressions and infarct size in rats with permanent middle cerebral artery occlusion. Stroke (1998) 29:190-195.
49. Parsons CG, Danysz W, Quack G, Hartmann S, Lorenz B, Wollenburg C, Baran L, Przegalinski E, Kostowski W, Krzascik P, Chizh B, Headley PM: Novel systemically active antagonists of the glycine site of the N-methyl-D-aspartate receptor: electrophysiological, biochemical and behavioral characterization. J Pharmcol Exp Ther (1997) 283:1264-1275.
50. Wenk GL, Baker LM, Stoehr JD, Hauss-Wegrzyniak B, Danysz W: Neuroprotection by novel antagonists at the NMDA receptor channel and glycine sites. Eur J Pharmacol (1998) 347:183-187.
51. Di Fabio R, Antolini M, Bertani B, Conti N, Donati D, Feriani A, Messeri T, Missio A, Pasquarello A, Pentassuglia G, Quaglia A, Reggiani A, Sabbatini F: SAR and neuroprotective activity of a novel class of glycine antagonists. ACS (1999) 217th Anaheim MEDI 278.
52. Colotta V, Catarzi D, Varano F, Cecchi L, Filacchtoni G, Galli A, Costagli C: Synthesis and biological evaluation of a series of quinazoline-2-carboxylic acids and quinazoline-2,4-diones as glycine-NMDA antagonists: a pharmacophore model based approach. Arch Pharm (1997) 330:129-134.
53. 3H]CGP 61594, the first photoaffinity ligand for the glycine site of NMDA receptors. Neuropharmacology (1999) 38:233-242.
54. Clark WM, Lutsep HL: American Heart Association - 24th International Joint Conference Stroke and Cerebral Circulation, Nashville, TN, USA. IDdb Meeting Report (1999) February 4-6.
55. Glaxo Wellcome: Product development pipeline June 1998. Company Brochure (1998) June.
56. Lees KR, Lavelle JF, Hobbiger SF: Safety and tolerability of GV150526 in acute stroke. (GLYB 2002). Cerebrovasc Dis (1998) 8(Suppl 4):20.
57. Dyker AG, Lees KR: Safety and tolerability of GV150526 (a glycine site antagonist at the N-methyl-D-aspartate receptor) in patients with acute stroke. Stroke (1999) 30:986-992.
58. Zeneca Group plc: Excellent growth prospects based on 87 projects including 26 new compounds in development Press Release (1997) December 1.
59. Wood PL, Hawkinson JE: N-Methyl-D-aspartate for stroke and head trauma. Exp Opin Invest Drugs (1997) 6:389-397.
60. Cocensys Inc: CoCensys and Novartis end collaboration on development of stroke compound CoCensys to seek new corporate partner. Press Release (1997) April 29.
61. Dunn LT: Head injury therapies. Exp Opin Invest Drugs (1997) 6:1511-1526.
62. Vyas SJ, Ramu K, Jackson EK, Data J, Lam GN, Branch RA: Probenecid reduces renal clearance of licostinel. Annu Meet Am Soc Clin Pharmacol (1998) 99 New Orleans PII-65.
63. Hawkinson JE, Huber KR, Sahota PS, Hsu HH, Weber E, Whitehouse MJ: The N-methyl-D-aspartate (NMDA) receptor glycine site antagonist ACEA 1021 does not produce pathological changes in rat brain. Brain Res (1997) 744:227-234.
64. Auer RN: Structural neurotoxicologic investigation of the glycine antagonist 5-nitro-6,7-dichloroquinoxalinedione (ACEA-1021). Neurotoxicology (1997) 18:53-62.
65. Lingenhohl K, Pozza MF: Reevaluation of ACEA 1021 as an antagonist at the strychnine-insensitive glycine site of the N-methyl-D-aspartate receptor. Neuropharmacol (1998) 37:729-737.
66. Albers GW, Clark WM, Atkinson RP, Madden K, Data JL, Whitehouse MJ: Dose escalation study of the NMDA glycine-site antagonist licostinel in acute ischemic stroke. Stroke (1999) 30:508-513.
67. Woodward RM, Huettner JE, Guastella J, Keana JFW, Weber E: In vitro pharmacology of ACEA-1021 and ACEA-1031: systemically active quinoxalinediones with high affinity and selectivity for N-methyl-D-aspartate receptor glycine sites. Mol Pharmacol (1995) 47:568-581.
68. Ilyin VI, Whittemore ER, Tran M, Shen KZ, Cai SX, Kher SM, Keana JFW, Weber E, Woodward RM: Pharmacology of ACEA-1416: a potent systemically active NMDA receptor glycine site antagonist. Eur J Pharmacol (1996) 310:107-114.
69. Zheng H, Espitia SA, Ilyin V, Hawkinson JE, Woodward RM, Weber E, Keana JFW: 1-Hydroxy-1,4-dihydroquinoxaline-2,3-diones: Novel antagonists at NMDA receptor glycine sites. Bioorg Med Chem Lett (1996) 6(4):439-440
70. Tranquillini ME, Reggiani A: Glycine-site antagonists and stroke. Exp Opin Invest Drugs (1999) 8(11):1837-1848.
71. Nikam SS, Kronberg BE, Schelkun RM, Ortwine DF, Cordon J, Vartanian MG, Nelson CB, Schwarz RD, Boxer P, Rafferty MF: Design and synthesis of new AMPA/GLY-N receptor antagonists. ACS (1998) 215th Dallas:MEDI 014.
72. NeuroSearch planning phase II for MMRI with fast onset of action. FDC Reports Pink Sheet (1998) 60(29):15-16.
73. Hoechst Marion Roussel: Drug development pipeline - HMR-2371 and HMR-2906. Company Communication (1999) May 21.
74. Greenamyre JT, Garcia Osuna M, MacKenzie G: Protection against striatal malonate toxicity by MRZ 2/576, a glycine site NMDA antagonist. Soc Neurosci Abstr (1997) 23(Part 2):1908.
75. Cai SX, Zhou ZL, Huang JC, Whittemore ER, Egbuwoku ZO, Lu Y, Hawkinson JE, Woodward RM, Weber E, Keana JFW: Synthesis and structure-activity relationships of 1,2,3,4-tetrahydroquinoline-2,3,4-trione 3-oximes: novel and highly potent antagonists for NMDA receptor glycine site. J Med Chem (1996) 39:3248-3255.
76. Open house presentation - CoCensys Inc. Annu Biopartnering Europe Meet (1998) October 26-27.
77. Cocensys: Cocensys announces restructuring and reports first quarter 1999 financial results. Company Communication (1999) April 27.
78. Scatton B, Avenet P, Benavides J, Besnard F, Duverger D, Graham D, Leonarden J, Santa-Maria R, Langer SZ: Therapeutic potential of drugs acting on excitatory amino acid receptors. Eur Neuropsychopharmacol (1995) 5:3 Abs S-4-2.
79. Maruoka Y, Ohno Y, Tanaka H, Yasuda H, Otani K et al: Effects of the novel tricyclic quinoxalinedione derivatives, SM-18400 and its analogs, on N-methyl-D-aspartate (NMDA) receptor-mediated synaptic transmission in the isolated neonatal rat spinal cord in vitro. Jpn J Pharmacol (1998) 76(3):265-270.
80. PFIZER INC (Bull DJ, Carr CL, Fray, MJ, Gautier EC): Quinaxalinediones. WO-09732873 (1997).
81. NOVARTIS AG (Acklin P, Allgeier H, Auberson Y, Biollaz M, Ofner S, Veenstra SJ): Novel 2,3-dioxo-1,2,3,4-tetrahydroquinoyxalinyl derivatives. WO-09708155 (1997).
82. ABBOTT LABORATORIES (Gaede B): A process for the preparation of highly pure 6,7-dichloro-5-nitro-2,3-dihydroquinoxaline-2,3-dione. WO-09847878 (1998).
83. WARNER-LAMBERT CO (Nikam SS): Tricyclic quinoxaline derivatives as neuroprotective agents. WO-09827097 (1998).
84. THE OREGON HEALTH SCIENCES UNIVERSITY (Cai SX, Keana JFW, Weber E): 8-Aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/NMDA receptor. US-05620978 (1997).
85. THE OREGON HEALTH SCIENCES UNIVERSITY (Cai SX, Weber E, Keana JFW): 4-Hydroxy-3-nitro-1,2-dihydroquinolin-2-ones and the use thereof as excitatory amino acid and glycine receptor antagonists. US-05622965 (1997).
86. THE OREGON HEALTH SCIENCES UNIVERSITY (Keana JFW, Cai SX, Zhou ZL, Navratil JM): Aza and aza (N-oxy) analogs of glycine/NMDA receptor antagonists. US-05801183 (1998).
87. KOREAN RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (Park NS, Seong CM, Jung YS, Choi JI, Lee CW, Chung YJ, Choi SW, Kong JY, Park WK): Quinolinic sulfide derivatives acting as NMDA receptor antagonists and process for preparation thereof. EP-00869122 (1998).
88. GLAXO SPA (Cugola A, Gaviraghi G, Micheli F): Preparation of indolecarboxylate derivatives as antagonists of excitatory amino acids. WO-09420465 (1994).
89. MERZ & CO (Danysz W, Gold M, Kalvinsh I, Parsons CGR, Piskunova I, Rozhkov E): Pyridazino [4,5-b]-quinoline 5-oxide derivatives, their preparation and their use as glycine antagonists. WO-09804556 (1998).
90. GLAXO WELLCOME SPA (Di Fabio R, Giacobbe S, Bertani B, Micheli F): Preparation of tetrahydroquinolines as NMDA antagonists. WO-09712870 (1997).
91. GLAXO WELLCOME SPA (Di Fabio R, Pasquarello A, Sabbatini FM): Preparation of tetrahydroquinolines as EAA antagonists. WO-09807704 (1998).
92. GLAXO WELLCOME SPA (Di Fabio R, Bertani B, Alvaro G): Preparation of a quinoline-2-carboxylic acid enantiomer as an excitatory amino acid antagonist. WO-09842673 (1998).